Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
复制标题
DOI：
10.1182/bloodadvances.2020001837
复制
发表时间：
2020-07-14
期刊：
影响因子：
7.5
通讯作者：
Nastoupil, Loretta J.
中科院分区：
文献类型：
--
作者：
Pinnix, Chelsea C.;Gunther, Jillian R.;Nastoupil, Loretta J.
在白细胞去除术和嵌合抗原受体（CAR）T细胞治疗大B细胞淋巴瘤（LBCL）之间进行桥接治疗（BT）的影响尚不清楚。我们评估了BT（全身治疗[ST]、放射治疗[RT]或联合治疗[CMT]）对148例LBCL患者结局的影响，这些患者接受了白细胞去除术，以计划进行axicabtagene ciloleucel（axi-cel）输注。55%（n = 81）接受BT治疗的患者更可能有国际预后指数（IPI）评分>= 3（P
The impact of bridging therapy (BT) administered between leukapheresis and chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is unclear. We evaluated the influence of BT (systemic therapy [ST], radiation therapy [RT], or combined-modality therapy [CMT]) on outcomes of 148 LBCL patients who underwent leukapheresis for planned axicabtagene ciloleucel (axi-cel) infusion. The 55% (n = 81) of patients who received BT were more likely to have international prognostic index (IPI) score >= 3 (P